The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
暂无分享,去创建一个
Andrew H. Beck | A. Khosla | A. Beck | Kwok-Kin Wong | P. Janne | C. Sanders | J. English | P. Kirschmeier | K. Packman | R. Verona | C. Moy | A. Dhaneshwar | M. Bittinger | M. Lorenzi | Wei Huang | E. Ivanova | E. Zudaire | J. Rytlewski | S. Laquerre | S. Palakurthi | S. Zacharek | D. Bonal | M. Kuraguchi | Kristin DePeaux | Jeffrey Liu | Martha R Gowaski | Dyane Bailey | Samuel N Regan | Catherine Ferrante | Samuel Regan | M. V. Lorenzi | Kwok-kin Wong | Sangeetha Palakurthi
[1] Xiaoting Yu,et al. Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer , 2018, Clinical Cancer Research.
[2] Stephen Broderick,et al. Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.
[3] Tim Beißbarth,et al. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards , 2018, Genome Medicine.
[4] T. Gajewski,et al. Impact of oncogenic pathways on evasion of antitumour immune responses , 2018, Nature Reviews Cancer.
[5] R. Emerson,et al. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells , 2017, Cancer Immunology Research.
[6] T. Bivona,et al. Understanding and targeting resistance mechanisms in NSCLC , 2017, Nature Reviews Cancer.
[7] William B. Goggins,et al. Incidence and mortality of lung cancer: global trends and association with socioeconomic status , 2017, Scientific Reports.
[8] N. Turner,et al. Advances and challenges in targeting FGFR signalling in cancer , 2017, Nature Reviews Cancer.
[9] A. Santiago-Walker,et al. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib , 2017, Molecular Cancer Therapeutics.
[10] C. Murray,et al. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor , 2017, Molecular Cancer Therapeutics.
[11] W. Cho,et al. Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer , 2017, Clinical and Translational Medicine.
[12] E. Mardis,et al. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape , 2017, Cancer Immunology Research.
[13] F. Safa,et al. Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy , 2017, Expert review of anticancer therapy.
[14] H. Ishwaran,et al. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade , 2016, Cell.
[15] M. Stanford,et al. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide , 2016, Journal of Immunotherapy for Cancer.
[16] Adam P. Rosebrock,et al. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma , 2016, Proceedings of the National Academy of Sciences.
[17] J. Blay,et al. Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma , 2016 .
[18] Ryan L. Kelly,et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses , 2016, Nature Medicine.
[19] S. Gettinger,et al. PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? , 2016, Clinical Cancer Research.
[20] Lawren C. Wu,et al. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. , 2016, Trends in immunology.
[21] M. Katoh. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review) , 2016, International journal of molecular medicine.
[22] S. Digumarthy,et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.
[23] G. Steinberg,et al. Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer , 2016, Cancer Immunology Research.
[24] Jing Wang,et al. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. , 2016, Cancer research.
[25] C. Jiang,et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] R. Wilkinson,et al. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model , 2016, Oncotarget.
[27] R. Weissleder,et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.
[28] M. Vignali,et al. T‐cell receptor profiling in cancer , 2015, Molecular oncology.
[29] J. Tabernero,et al. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[31] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[32] William S. DeWitt,et al. Dynamics of the Cytotoxic T Cell Response to a Model of Acute Viral Infection , 2015, Journal of Virology.
[33] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[34] M. Meyerson,et al. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. , 2014, Cancer research.
[35] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[36] Yuquan Wei,et al. Reductions in Myeloid-Derived Suppressor Cells and Lung Metastases using AZD4547 Treatment of a Metastatic Murine Breast Tumor Model , 2014, Cellular Physiology and Biochemistry.
[37] Yuquan Wei,et al. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis , 2014, Breast Cancer Research and Treatment.
[38] R. Emerson,et al. Using synthetic templates to design an unbiased multiplex PCR assay , 2013, Nature Communications.
[39] Jeanne Shen,et al. Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[40] Laurence Zitvogel,et al. Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.
[41] Bruce E Johnson,et al. The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[42] T. Griffin,et al. Fibroblast Growth Factor Receptor 1 Activation in Mammary Tumor Cells Promotes Macrophage Recruitment in a CX3CL1-Dependent Manner , 2012, PloS one.
[43] C. Desmarais,et al. Ultra-sensitive detection of rare T cell clones. , 2012, Journal of immunological methods.
[44] J. Wesche,et al. Fibroblast growth factors and their receptors in cancer. , 2011, The Biochemical journal.
[45] I. Petersen,et al. Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.
[46] A. Ashworth,et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.
[47] N. Turner,et al. Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.
[48] Hugo M. Horlings,et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets , 2009, Oncogene.
[49] Abigail Wacher,et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. , 2009, Blood.
[50] T. Jacks,et al. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.
[51] K. Sakaguchi,et al. FRAG1, a gene that potently activates fibroblast growth factor receptor by C-terminal fusion through chromosomal rearrangement. , 1996, Proceedings of the National Academy of Sciences of the United States of America.